Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market
Laiba Immad
Wed, February 18, 2026 at 3:10 PM GMT+9 1 min read
In this article:
TVTX
+3.34%
Travere Therapeutics, Inc. (NASDAQ:TVTX) is among the 15 Innovative Healthcare Stocks to Buy According to Analysts.
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market
Travere Therapeutics, Inc. (NASDAQ:TVTX) is placed ninth on our list.
TheFly reported on February 6 that Piper Sandler raised its price target on TVTX to $38 from $35 and maintained a Neutral rating on the shares. The adjustment comes following several Q4 and full-year 2025 pre-announcements and ahead of the company’s upcoming Q4 report. The firm used this period to review and update its estimates for select commercial names, including Travere, which prompted the revised price target.
Earlier on February 3, BofA also raised its price target on Travere Therapeutics, Inc. (NASDAQ:TVTX) to $44 from $43 and gave it a Buy rating. The firm noted that, given the recent pre-announcements, the upcoming Q4 earnings report may not have the same impact as in previous years. The price target adjustment reflects BofA’s updated view of the company within its biopharma coverage ahead of the quarterly results.
Travere Therapeutics, Inc. (NASDAQ:TVTX) is a U.S. biopharmaceutical company focused on innovative rare disease therapies, developing and commercializing novel treatments like FILSPARI and enzyme replacement candidates for unmet renal and metabolic conditions, and leveraging patient‑centric science and strategic collaborations to drive breakthrough care.
While we acknowledge the potential of TVTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 10 Most Profitable Undervalued Stocks to Buy and 11 Best Mining Stocks to Buy According to Wall Street.
Disclosure: None.
Terms and Privacy Policy
Privacy Dashboard
More Info